Amendment to the Claims

This listing of claims will replace all prior versions and listings of claims.

1-23. (Canceled)

24. (New) An isolated polypeptide comprising an amino acid sequence at least 95% identical to a second polypeptide sequence selected from the group consisting of:

(a) a polypeptide comprising amino acid residues 1 to 264 of SEQ ID NO:180;

(b) a polypeptide comprising amino acid residues 2 to 264of SEQ ID NO:180;

(c) a polypeptide comprising amino acid residues 17 to 264 of SEQ ID NO:180;

(d) a polypeptide comprising the amino acid sequence of the complete polypeptide encoded by the HLWBO56 cDNA contained in ATCC Deposit No. PTA-3105;

(e) a polypeptide comprising the amino acid sequence of the complete polypeptide encoded by the HLWBO56 cDNA contained in ATCC Deposit No. PTA-3105, excepting the N-terminal methionine;

(f) a polypeptide comprising the amino acid sequence of the mature portion of the polypeptide encoded by the HLWBO56 cDNA contained in ATCC Deposit No. PTA-3105;

(g) a polypeptide comprising at least 30 contiguous amino acid residues of amino acid residues 1 to 264 of SEQ ID NO:180; and

(h) a polypeptide comprising at least 50 contiguous amino acid residues of amino acid residues 1 to 264 of SEQ ID NO:180.

25. (New) The isolated polypeptide of claim 24(a).

26. (New) The isolated polypeptide of claim 24(c).

27. (New) The isolated polypeptide of claim 24(f)

28. (New) The isolated polypeptide of claim 24(g).

29. (New) The isolated polypeptide of claim 24, wherein said polypeptide is glycosylated.

30. (New) A composition comprising the isolated polypeptide of claim 24 and a pharmaceutically acceptable carrier.

31. (New) An isolated polypeptide comprising a polypeptide sequence selected from the group consisting of:

(a) a polypeptide comprising amino acid residues 1 to 264 of SEQ ID NO:180;

(b) a polypeptide comprising amino acid residues 2 to 264 of SEQ ID NO:180;

(c) a polypeptide comprising amino acid residues 17 to 264 of SEQ ID NO:180;

(d) a polypeptide comprising the amino acid sequence of the complete polypeptide encoded by the HLWBO56 cDNA contained in ATCC Deposit No. PTA-3105;

(e) a polypeptide comprising the amino acid sequence of the complete polypeptide encoded by the HLWBO56 cDNA contained in ATCC Deposit No. PTA-3105, excepting the N-terminal methionine

(f) a polypeptide comprising the amino acid sequence of the mature portion of the polypeptide encoded by the HLWBO56 cDNA contained in ATCC Deposit No. PTA-3105;

(g) a polypeptide comprising at least 30 contiguous amino acid residues of amino acid residues 1 to 264 of SEQ ID NO:180; and

(h) a polypeptide comprising at least 50 contiguous amino acid residues of amino acid residues 1 to 264 of SEQ ID NO:180.

32. (New) The isolated polypeptide of claim 31(a).

33. (New) The isolated polypeptide of claim 31(c).

34. (New) The isolated polypeptide of claim 31(g).

35. (New) The isolated polypeptide of claim 31 which comprises a heterologous polypeptide sequence.

36. (New) A composition comprising the polypeptide of claim 31 and a pharmaceutically acceptable carrier.

37. (New) A recombinant host cell that expresses the isolated polypeptide of claim 31.

38. (New) A method of making an isolated polypeptide comprising:

(a) culturing the recombinant host cell of claim 37 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

39. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 31.

40. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 31 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

41. A method for identifying a binding partner to the polypeptide of claim 31 comprising:

(a) contacting the polypeptide of claim 31 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.